Document:

Exhibit

EXHIBIT 10.5
THE HOWARD HUGHES CORPORATION 
RESTRICTED STOCK AGREEMENT
WHEREAS, [INSERT NAME] (the “Grantee”) is an employee of The Howard Hughes Corporation (and its successors, the “Company”);

WHEREAS, the grant of Restricted Stock was authorized by the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) on February 20, 2019;

WHEREAS, the date of grant is February 20, 2019 (“Date of Grant”); and

WHEREAS, pursuant to The Howard Hughes Corporation Amended and Restated 2010 Incentive Plan (the “Plan”), and subject to the terms and conditions thereof and the terms and conditions of this agreement (this “Agreement”), the Company has granted to Grantee as of the Date of Grant the right to receive <INSERT AMOUNT> shares of common stock of the Company (the “Restricted Shares”).

NOW, THEREFORE, the Company and Grantee hereby agree as follows:

1.Rights of Grantee.  The Restricted Shares subject to this grant shall be fully paid and nonassessable and shall be either: (i) represented by certificates held in custody by the Company until all restrictions thereon have lapsed, together with a stock power or powers executed by Grantee in whose name such certificates are registered, endorsed in blank and covering such Restricted Shares; or (ii) held at the Company’s transfer agent in book entry form with appropriate restrictions relating to the transfer of such Restricted Shares, and endorsed with an appropriate legend referring to the restrictions hereinafter set forth. Grantee shall have the right to vote the Restricted Shares. Upon vesting of the Restricted Shares hereunder, the Grantee: (x) shall receive cash dividends or cash distributions, if any, paid or made by the Company with respect to common shares after the Date of Grant and prior to the vesting of the Restricted Stock; and (y) shall receive any additional Restricted Shares that Grantee may become entitled to receive by virtue of a Restricted Share dividend, a merger or reorganization in which the Company is the surviving corporation or any other change in the capital structure of the Company.

2.Restrictions on Transfer of Restricted Shares. The Restricted Shares subject to this grant may not be assigned, exchanged, pledged, sold, transferred or otherwise disposed of by Grantee, except to the Company, until the Restricted Shares have become nonforfeitable in accordance with Sections 3, 4 and 5 hereof. The Grantee’s rights with respect to such purported transfer in violation of the provisions of this Section 2 of this Agreement shall be null and void, and the purported transferee shall obtain no rights with respect to such Restricted Shares.

3.Vesting of Restricted Shares. Subject to the terms and conditions of Sections 4 and 5 of this Agreement, the Restricted Shares covered by this Agreement shall vest in accordance with the vesting schedule based on the total shareholder return as set forth on Exhibit A (the “Performance-based Vesting Component”).

4.Forfeiture of Awards. The Grantee’s rights to receive the unvested Restricted Shares covered by this Agreement shall be forfeited automatically and without further notice on the date that Grantee ceases to be an employee of the Company or a Subsidiary.

5.Death or Disability.  Notwithstanding Sections 3 and 4 of this Agreement, if the Grantee dies or suffers a Permanently Disability (as defined below) before the vesting of the Performance-based Vesting Component, then 100% of the Performance-based Vesting Component shall vest and become nonforfeitable.  “Permanent Disability” means, unless otherwise provided by the Compensation Committee (talking into account the requirements of Section 409A of the Code, if applicable), the inability of an employee to perform the material duties of his or her employment by reason of a medically determinable physical or mental impairment that can be expected to result in death or that has lasted or is expected to last for a continuous period of at least twelve (12) months, as determined by a duly licensed physician selected by the Committee.

1

6.Compliance with Law. The Company shall make reasonable efforts to comply with all applicable federal and state securities laws; provided, however, that notwithstanding any other provision of this Agreement, the Company shall not be obligated to issue any of the Restricted Shares covered by this Agreement if the issuance thereof would result in violation of any such law.

7.Compliance with Section 409A of the Code. To the extent applicable, it is intended that this Agreement and the Plan comply with the provisions of Section 409A of the Code, so that the income inclusion provisions of Section 409A(a)(1) of the Code do not apply to Grantee. This Agreement and the Plan shall be administered in a manner consistent with this intent. Reference to Section 409A of the Code is to Section 409A of the Internal Revenue Code of 1986, as amended, and will also include any proposed, temporary or final regulations, or any other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service.

8.Amendments. Any amendment to the Plan shall be deemed to be an amendment to this Agreement to the extent that the amendment is applicable hereto; provided, however, that no amendment shall adversely affect the rights of Grantee under this Agreement without Grantee’s consent; further, provided, that Grantee’s consent shall not be required to an amendment that is deemed necessary by the Company to ensure compliance with Section 409A of the Code or the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 or any regulations promulgated thereunder, including as a result of the implementation of any recoupment policy the Company adopts to comply with the requirements set forth in the Dodd-Frank Act.

9.Severability. In the event that one or more of the provisions of this Agreement shall be invalidated for any reason by a court of competent jurisdiction, any provision so invalidated shall be deemed to be separable from the other provisions hereof, and the remaining provisions hereof shall continue to be valid and fully enforceable.

10.Relation to Plan. This Agreement is subject to the terms and conditions of the Plan. In the event of any inconsistency between the provisions of this Agreement and the Plan, the Plan shall govern. Capitalized terms used herein without definition shall have the meanings assigned to them in the Plan. The Compensation Committee acting pursuant to the Plan, as constituted from time to time, shall, except as expressly provided otherwise herein or in the Plan, have the right to determine any questions which arise in connection with the grant of Restricted Shares.

11.Successors and Assigns. Without  limiting Section 2 hereof, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Grantee, and the successors and assigns of the Company.

12.Governing Law. This Agreement is made under, and shall be construed in accordance with, the internal substantive laws of the State of Delaware without giving effect to the principles of conflict of laws thereof.

2

Executed in the name and on behalf of the Company, as of the 20th day of February, 2019.

THE HOWARD HUGHES CORPORATION

By:_______________________________________
Name: David R. Weinreb
Title: Chief Executive Officer

The undersigned Grantee hereby acknowledges receipt of an executed original of this Agreement and accepts the right to receive the Restricted Shares or other securities covered hereby, subject to the terms and conditions of the Plan and the terms and conditions herein above set forth.

Employee (Grantee)

Date:_______________________________________

3

EXHIBIT A

PERFORMANCE-BASED VESTING SCHEDULE

	
			
	Cumulative Compounded Annual Total Shareholder Return
	

Stock Price End
	

Vesting %

	0.00% to 10.99%
	$172.56  or below
	0%

	11.00% to 11.99%
	$172.57
	30%

	12.00% to 12.99%
	$180.48
	60%

	13.00% to 13.99%
	$188.68
	90%

	14.00% to 14.99%
	$197.18
	120%

	15.00%+
	205.98+
	150%

The Performance-based Vesting Component of the Award shall vest on December 31, 2023, according to the schedule above; provided, that the Company achieves the corresponding cumulative compounded annual total shareholder return (“TSR”) target. $102.41, the volume weighted average share price of the Company for the last 30 trading days of 2018, shall be used as the beginning price for the purpose of calculating TSR. The ending price for the purpose of calculating TSR shall be the volume weighted average share price of the Company for the last 30 trading days of 2023. A TSR target is deemed satisfied if the TSR (calculated as described above) meets or exceeds such target. If the “Stock Price End” amount is higher than the threshold “Stock Price End” amount, but less than the “Stock Price End” amount for the next highest threshold, then, in this instance, the percentage of the award that vests shall be interpolated between the two thresholds. For example, if your award was for 1,000 shares and on December 31, 2023 the “Stock Price End” was $201.58 (i.e. mid-way between $197.18 and $205.98), then, in this instance, you would be entitled to 1,350 fully vested shares of HHC Common Stock (135% of 1,000 shares). Share price shall be based on the daily closing price of the Company’s common stock as reported in the consolidated transaction reporting system and shall be rounded to the nearest whole cent.

The Compensation Committee may make adjustments to the terms and conditions of, and the criteria included in, Awards in recognition of unusual or nonrecurring events, including without limitation, stock splits, stock dividends, spinoffs or other similar events, or as a result of changes in applicable laws, regulations or accounting principles, to prevent dilution or enlargement of the benefits or increase in intended benefits or potential intended benefits provided by an Award; provided, that such adjustments shall be consistent with the requirements of Section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”) with regard to Awards subject to Section 162(m) of the Code.

The term “Award” shall have the meaning set forth in The Howard Hughes Corporation 2010 Amended and Restated Incentive Plan. All other capitalized terms used herein without definition shall have the meanings assigned to them in the Restricted Stock Agreement to which this Exhibit A is attached.Exhibit 10.10

 

ESCROW
DEPOSIT AGREEMENT

 

This
ESCROW DEPOSIT AGREEMENT (this “Agreement”) dated as of this [__] day of [_____] 201[_], by and among
Happiness Biotech Group Limited, a Cayman Islands company (the “Company”),
having an address at No. 11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City, Fujian Province, People’s Republic of
China, Univest Securities, LLC, a New York limited liability company. (the
“Underwriter”), having an address at 375 Park Avenue, Suite 1502, New York, NY 10152, and SIGNATURE BANK
(the “Escrow Agent”), a New York State chartered bank, having an office at 950 Third Ave., 9th
floor, New York, NY 10022. All capitalized terms not herein defined shall have the meaning ascribed to them in that certain Prospectus,
dated March 28, 2019, including all attachments, schedules and exhibits thereto (the “Prospectus”).

 

W
I T N E S S E T H:

 

WHEREAS,
pursuant to the Prospectus, the Company desires to sell (the “Offering”) a minimum of $5,500,000 (the “Minimum
Amount”) and a maximum of $11,000,000 (the “Maximum Amount”) of its ordinary shares (the “Shares”),
par value $0.0005 per Share. Each Share is being sold at a price of $5.50 per Share; and

 

WHEREAS,
unless the Minimum Amount is sold by [insert Termination Date] (the “Termination Date”), or by [insert
Final Termination Date]  (the “Final Termination Date”) if the Termination Date has been extended
by Company and the Underwriter, the Offering shall terminate and all funds shall be returned to the subscribers in the Offering,
and if the Minimum Amount is met, the Offering may continue until the Termination Date or Final Termination Date if extended;
and

 

WHEREAS,
the Company and Underwriter desire to establish an escrow account with the Escrow Agent into which the Company and Underwriter
shall instruct Investors introduced to the Company by Underwriter (the “Investors”) to deposit checks and other
instruments for the payment of money made payable to the order of “Signature Bank as Escrow Agent for Happiness Biotech
Group Ltd ,” and Escrow Agent is willing to accept said checks and other instruments for the payment of money in accordance
with the terms hereinafter set forth; and

 

WHEREAS,
the Company, as issuer, and Underwriter, as an introducing broker-dealer, represent and warrant to the Escrow Agent that they
will comply with all of their respective obligations under applicable state and federal securities laws and regulations with respect
to sale of the Offering; and

 

WHEREAS,
the Company and Underwriter represent and warrant to the Escrow Agent that they have not stated to any individual or entity that
the Escrow Agent’s duties will include anything other than those duties stated in this Agreement; and

 

WHEREAS,
the Company and Underwriter warrant to the Escrow Agent that a copy of each document that has been delivered to Investors and
third parties that include Escrow Agent’s name and duties, has been attached hereto as Schedule I.

 

     

     

    

 

NOW,
THEREFORE, IT IS AGREED as follows:

 

1. Delivery
of Escrow Funds.

 

(a)
 Underwriter and the Company shall instruct Investors to deliver to Escrow Agent checks
made payable to the order of “Signature Bank, as Escrow Agent for Happiness Biotech Group Limited,” or wire transfer
to Signature Bank, 950 Third Ave., 9th floor, New York, NY 10022, ABA No. 026013576 for credit to Signature Bank, as
Escrow Agent for Happiness Biotech Group Ltd , Account No. _____________, in each case, with the name and address of the individual
or entity making payment. In the event any Investor’s address is not provided to Escrow Agent by the Investor, then Underwriter
and/or the Company agree to promptly provide Escrow Agent with such information in writing. The checks or wire transfers shall
be deposited into a non interest-bearing account at Signature Bank entitled “Happiness Biotech Group Ltd., Signature Bank,
as Escrow Agent” (the “Escrow Account”).

 

(b) The
collected funds deposited into the Escrow Account are referred to as the “Escrow Funds.”

 

(c) The
Escrow Agent shall have no duty or responsibility to enforce the collection or demand payment of any funds deposited into the
Escrow Account. If, for any reason, any check deposited into the Escrow Account shall be returned unpaid to the Escrow Agent,
the sole duty of the Escrow Agent shall be to return the check to the Investor and advise the Company and Underwriter promptly
thereof.

 

2. Release
of Escrow Funds. The Escrow Funds shall be paid by the Escrow Agent in accordance with the following:

 

(a) In
the event that the Company and Underwriter advise the Escrow Agent in writing that the Offering has been terminated (the “Termination
Notice”), the Escrow Agent shall promptly return the funds paid by each Investor to said Investor without interest or
offset.

 

(b)
If prior to 3:00 P.M. Eastern time on the Termination Date, the Escrow Agent receives written notice, in the form of Exhibit
A, attached hereto and made a part hereof, and signed by the Company and Underwriter, stating that the Termination Date has been
extended to the Final Termination Date (the “Extension Notice”), then the Termination Date shall be so extended.

 

(c)
 Provided that the Escrow Agent does not receive the Termination Notice in accordance
with Section 2(a) and there is the Minimum Amount deposited into the Escrow Account on or prior to later of the Termination Date
or the date stated in the Extension Notice, if any, received by the Escrow Agent in accordance with Section 2(b) above, the Escrow
Agent shall, upon receipt of written instructions, in the form of Exhibit B, attached hereto and made a part hereof, or in a form
and substance satisfactory to the Escrow Agent, received from the Company and Underwriter, pay the Escrow Funds in accordance
with such written instructions, such payment or payments to be made by wire transfer within one (1) business day of receipt of
such written instructions. Such instructions must be received by the Escrow Agent no later than 3:00 PM Eastern Time on a Banking
Day for the Escrow Agent to process such instructions that Banking Day.

 

    2

     

    

 

(d) If
by 3:00 P.M. Eastern time on the later of the Termination Date or the date stated in the Extension Notice, if any, that the Escrow
Agent has received in accordance with Section 2(b) above, the Escrow Agent has not received written instructions from the Company
and Underwriter regarding the disbursement of the Escrow Funds or the total amount of the Escrow Funds is less than the Minimum
Amount, then the Escrow Agent shall promptly return the Escrow Funds to the Investors without interest or offset and close the
Escrow Account immediately thereafter. The Escrow Funds returned to each Investor shall be free and clear of any and all claims
of the Escrow Agent.

 

(e) The
Escrow Agent shall not be required to pay any uncollected funds or any funds that are not available for withdrawal.

 

(f) If
the Termination Date, Final Termination Date or any date that is a deadline under this Agreement for giving the Escrow Agent notice
or instructions or for the Escrow Agent to take action is not a Banking Day, then such date shall be the Banking Day that immediately
preceding that date. A “Banking Day” is any day other than a Saturday, Sunday or a day that a New York State
chartered bank is not legally obligated to be opened.

 

3. Acceptance
by Escrow Agent. The Escrow Agent hereby accepts and agrees to perform its obligations hereunder, provided that:

 

(a) Upon
execution of this Agreement, the Company shall execute and deliver to Escrow Agent Exhibit C hereto and the Underwriter shall
execute and deliver to Escrow Agent Exhibit C-1 hereto (together with Exhibit C, each a “Certificate”), for
the purpose of (i) establishing the identity of each respective authorized representative(s) of the Company and the Underwriter
entitled to singly initiate and/or confirm disbursement instructions to Escrow Agent on behalf of each such party and (ii) providing
standing wire instructions for each of the Company and Underwriter to be used for disbursements to said party. The Escrow Agent
may act in reliance upon any signature on each Certificate believed by it to be genuine, and may assume that any person who has
been designated by Underwriter or the Company to give any written instructions, notice or receipt, or make any statements in connection
with the provisions hereof has been duly authorized to do so. The Escrow Agent shall have no duty to make inquiry as to the genuineness,
accuracy or validity of any statements or instructions or any signatures on statements or instructions, including but not limited
to, those contained on each Certificate. The Company and the Underwriter may update their respective Certificate by executing
and delivering to the Escrow Agent an updated Certificate substantially in the form attached hereto as Exhibit C and/or Exhibit
C-1. Until such time as Escrow Agent shall receive an updated Certificate, Escrow Agent shall be fully protected in relying without
inquiry on the current Certificate on file with Escrow Agent.

 

(b) The
Escrow Agent may seek confirmation of disbursement instructions by telephone call back to one of the authorized representatives
set forth on each Certificate, and the Escrow Agent may rely upon the confirmations of anyone purporting to be the person(s)
so designated. To ensure the accuracy of the instruction it receives, the Escrow Agent may record such call back. If the Escrow
Agent is unable to verify the instruction, or is not satisfied in its sole discretion with the verification it receives, it will
not execute the instruction until all issues have been resolved to its satisfaction. The Company and Underwriter agree that the
foregoing procedures constitute commercially reasonable security procedures. Escrow Agent further agrees not to comply with any
direction or instruction (other than those contained herein or delivered in accordance with this Agreement) from any party inconsistent
with the foregoing.

 

    3

     

    

 

(c) The
Escrow Agent may act relative hereto in reliance upon advice of counsel in reference to any matter connected herewith. The Escrow
Agent shall not be liable for any mistake of fact or error of judgment or law, or for any acts or omissions of any kind, unless
caused by its willful misconduct or gross negligence.

 

(d) Underwriter
and the Company agree to indemnify and hold the Escrow Agent harmless from and against any and all claims, losses, costs, liabilities,
damages, suits, demands, judgments or expenses (including but not limited to reasonable attorney’s fees) claimed against
or incurred by Escrow Agent arising out of or related, directly or indirectly, to this Escrow Agreement unless caused by the Escrow
Agent’s gross negligence or willful misconduct.

 

(e) In
the event that the Escrow Agent shall be uncertain as to its duties or rights hereunder, the Escrow Agent shall be entitled to
(i) refrain from taking any action other than to keep safely the Escrow Funds until it shall be directed otherwise by a court
of competent jurisdiction, or (ii) deliver the Escrow Funds to a court of competent jurisdiction.

 

(f) The
Escrow Agent shall have no duty, responsibility or obligation to interpret or enforce the terms of any agreement other than Escrow
Agent’s obligations hereunder, and the Escrow Agent shall not be required to make a request that any monies be delivered
to the Escrow Account, it being agreed that the sole duties and responsibilities of the Escrow Agent shall be to the extent not
prohibited by applicable law (i) to accept checks or other instruments for the payment of money and wire transfers delivered to
the Escrow Agent for the Escrow Account and deposit said checks and wire transfers into the non-interest bearing Escrow Account,
and (ii) to disburse or refrain from disbursing the Escrow Funds as stated above, provided that the checks received by the Escrow
Agent have been collected and are available for withdrawal.

 

4. Escrow
Account Statements and Information. The Escrow Agent agrees to send to the Company and/or the Underwriter a copy of the Escrow
Account periodic statement, upon request in accordance with the Escrow Agent’s regular practices for providing account statements
to its non-escrow clients and to also provide the Company and/or Underwriter, or their designee, upon request other deposit account
information, including Escrow Account balances, by telephone or by computer communication, to the extent practicable. The Company
and Underwriter agree to complete and sign all forms or agreements required by the Escrow Agent for that purpose. The Company
and Underwriter each consent to the Escrow Agent’s release of such Escrow Account information to any of the individuals
designated by Company or Underwriter, which designation has been signed in accordance with Section 3(a) by any of the persons
on the Company and Underwriter’s respective Certificate.  Further, the Company and Underwriter have an option to receive
e-mail notification of incoming and outgoing wire transfers. If this e-mail notification service is requested and subsequently
approved by the Escrow Agent, the Company and Underwriter agrees to provide a valid e-mail address and other information necessary
to set-up this service and sign all forms and agreements required for such service. The Company and Underwriter each consent to
the Escrow Agent’s release of wire transfer information to the designated e-mail address(es). The Escrow Agent’s liability
for failure to comply with this section shall not exceed the cost of providing such information.

 

    4

     

    

 

5. Resignation
and Termination of the Escrow Agent. The Escrow Agent may resign at any time by giving 30 days’ prior written notice
of such resignation to Underwriter and the Company. Upon providing such notice, the Escrow Agent shall have no further obligation
hereunder except to hold as depositary the Escrow Funds that it receives until the end of such 30-day period. In such event, the
Escrow Agent shall not take any action, other than receiving and depositing Investors checks and wire transfers in accordance
with this Agreement, until the Company has designated a banking corporation, trust company, attorney or other person as successor.
Upon receipt of such written designation signed by Underwriter and the Company, the Escrow Agent shall promptly deliver the Escrow
Funds to such successor and shall thereafter have no further obligations hereunder. If such instructions are not received within
30 days following the effective date of such resignation, then the Escrow Agent may (i) deposit the Escrow Funds held by it pursuant
to this Agreement with a clerk of a court of competent jurisdiction pending the appointment of a successor; or (ii) return all
funds remaining in the Escrow Account to the Investors in the Offering, in the same manner as such funds were received (and Company
and Underwriter agree to cooperate with Escrow Agent in providing any information required to facilitate such a return of funds
to the Investors). In either case provided for in this Section, the Escrow Agent shall be relieved of all further obligations
and released from all liability thereafter arising with respect to the Escrow Funds.

 

6. Termination.
The Company and Underwriter may terminate the appointment of the Escrow Agent hereunder upon written notice specifying the date
upon which such termination shall take effect, which date shall be at least 30 days from the date of such notice. In the event
of such termination, the Company and Underwriter shall, within 30 days of such notice, appoint a successor escrow agent and the
Escrow Agent shall, upon receipt of written instructions signed by the Company and Underwriter, turn over to such successor escrow
agent all of the Escrow Funds; provided, however, that if the Company and Underwriter fail to appoint a successor
escrow agent within such 30-day period, such termination notice shall be null and void and the Escrow Agent shall continue to
be bound by all of the provisions hereof. Upon receipt of the Escrow Funds, the successor escrow agent shall become the escrow
agent hereunder and shall be bound by all of the provisions hereof and Escrow Agent shall be relieved of all further obligations
and released from all liability thereafter arising with respect to the Escrow Funds and under this Agreement.

 

7. Investment.
All funds received by the Escrow Agent shall be held only in non-interest bearing bank accounts at Signature Bank.

 

8. Compensation.
Escrow Agent shall be entitled, for the duties to be performed by it hereunder, to a fee of $4,000.00, which fee shall be paid
by the Company upon the signing of this Agreement. In addition, the Company shall be obligated to reimburse Escrow Agent for all
fees, costs and expenses incurred or that become due in connection with this Agreement or the Escrow Account, including reasonable
attorney’s fees. Neither the modification, cancellation, termination or rescission of this Agreement nor the resignation
or termination of the Escrow Agent shall affect the right of Escrow Agent to retain the amount of any fee which has been paid,
or to be reimbursed or paid any amount which has been incurred or becomes due, prior to the effective date of any such modification,
cancellation, termination, resignation or rescission. To the extent the Escrow Agent has incurred any such expenses, or any such
fee becomes due, prior to any closing, the Escrow Agent shall advise the Company and the Company shall direct all such amounts
to be paid directly at any such closing.

 

    5

     

    

 

9. Notices.
All notices, requests, demands and other communications required or permitted to be given hereunder shall be in writing and shall
be deemed to have been duly given if sent by hand-delivery, by facsimile (followed by first-class mail), by nationally recognized
overnight courier service or by prepaid registered or certified mail, return receipt requested, to the addresses set forth below:

 

If
to Underwriter:

 

Univest
Securities, LLC

375
Park Avenue Unit 1502

New
York, NY 10152

Attention:
Edric Guo

Fax:
212-966-0648

 

If
to the Company:

 

No.
11, Dongjiao East Road, Shuangxi, Shunchang, Nanping City_

Fujian
Province, People’s Republic of China

Attention:
Xuezhu Wang, Chairman

Fax:

 

If
to Escrow Agent:

 

Signature
Bank

950
Third Ave., 9th Floor

New
York, NY 10022

Attention:
John D. Gonzalez, GD - SVP

Fax:
646-822-1520

 

10. General.

 

(a) This
Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York applicable to agreements
made and to be entirely performed within such State, without regard to choice of law principles and any action brought hereunder
shall be brought in the courts of the State of New York, located in the County of New York. Each party hereto irrevocably waives
any objection on the grounds of venue, forum nonconveniens or any similar grounds and irrevocably consents to service of process
by mail or in any manner permitted by applicable law and consents to the jurisdiction of said courts. EACH OF THE PARTIES HERETO
HEREBY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF THE TRANSACTIONS CONTEMPLATED
BY THIS AGREEMENT.

 

    6

     

    

 

(b) This
Agreement sets forth the entire agreement and understanding of the parties with respect to the matters contained herein and supersedes
all prior agreements, arrangements and understandings relating thereto.

 

(c) All
of the terms and conditions of this Agreement shall be binding upon, and inure to the benefit of and be enforceable by, the parties
hereto, as well as their respective successors and assigns.

 

(d) This
Agreement may be amended, modified, superseded or canceled, and any of the terms or conditions hereof may be waived, only by a
written instrument executed by each party hereto or, in the case of a waiver, by the party waiving compliance. The failure of
any party at any time or times to require performance of any provision hereof shall in no manner affect its right at a later time
to enforce the same. No waiver of any party of any condition, or of the breach of any term contained in this Agreement, whether
by conduct or otherwise, in any one or more instances shall be deemed to be or construed as a further or continuing waiver of
any such condition or breach or a waiver of any other condition or of the breach of any other term of this Agreement. No party
may assign any rights, duties or obligations hereunder unless all other parties have given their prior written consent.

 

(e) If
any provision included in this Agreement proves to be invalid or unenforceable, it shall not affect the validity of the remaining
provisions.

 

(f) This
Agreement and any modification or amendment of this Agreement may be executed in several counterparts or by separate instruments
and all of such counterparts and instruments shall constitute one agreement, binding on all of the parties hereto.

 

11. Form
of Signature. The parties hereto agree to accept a facsimile transmission copy of their respective actual signatures as evidence
of their actual signatures to this Agreement and any modification or amendment of this Agreement; provided, however,
that each party who produces a facsimile signature agrees, by the express terms hereof, to place, promptly after transmission
of his or her signature by fax, a true and correct original copy of his or her signature in overnight mail to the address of the
other party.

 

12.
 No Third-Party Beneficiaries.  This Agreement is solely for the benefit
of the parties and their respective successors and permitted assigns, and no other person has any right, benefit, priority, or
interest under or because of the existence of this Agreement.

 

    7

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first set forth above.

 

	UNIVEST
    SECURITIES, LLC	 
	 	 	 	 
	By:	 	 
	 	Name:	Edric
    Guo	 
	 	Title:	COO	 
	 	 	 	 
	HAPPINESS
    BIOTECH GROUP LIMITED	 
	 	 	 
	By:	 	 
	 	Name:	Xuezhu
    Wang	 
	 	Title:	Chairman	 
	 	 	 	 
	SIGNATURE
    BANK	 
	 	 	 
	By:	 	 
	 	Name:	John
    D. Gonzalez	 
	 	Title:	Group
    Director - SVP	 
	 	 	 	 
	By:	 	 
	 	Name:	Sherry
    Ann Cavera	 
	 	Title:	Relationship
    Manager - VP	 

 

    8

     

    

 

Schedule
I

 

OFFERING
DOCUMENTS

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    9

     

    

 

Schedule
II

 

The
Escrow Agent is authorized to accept instructions signed or believed by the Escrow Agent to be signed by any one of the following
on behalf of the Company and Underwriter.

 

	HAPPINESS
    BIOTECH GROUP LIMITED
	 	 
	                          Name	                          True
    Signature
	 	 
	_________________________________	_________________________________
	 	 
	UNIVEST
    SECURITIES, LLC
	 	 
	                          Name	                          True
    Signatures
	 	 
	_________________________________	_________________________________
	 	 
	_________________________________	_________________________________

 

     

     

    

 

Exhibit
A

 

EXTENSION
NOTICE

 

Date:

 

Signature
Bank

950
Third Ave., 9th Floor

New
York, NY 10022______________

Attention:
Sherry Ann Cavera, Relationship Manager - VP

 

Dear
Ms. Cavera:

 

In
accordance with the terms of Section 2(b) of an Escrow Deposit Agreement dated ___ _______, by and among Happiness Biotech Group
Limited (the “Company”), Univest Securities, LLC (“Underwriter”), and Signature Bank (the “Escrow
Agent”), the Company and Underwriter hereby notifies the Escrow Agent that the Termination Date has been extended to __________
__, 20__, the Final Termination Date.

 

Very
truly yours,

 

Happiness
Biotech Group Limited

 

By:_____________

Name:__________

Title:____________

 

Univest
Securities LLC

 

By:_____________

Name:___________

Title:____________

 

     

     

    

 

Exhibit
B

 

FORM
OF ESCROW RELEASE NOTICE

 

Date:

 

Signature
Bank

950
Third Ave., 9th Floor

New
York, NY 10022Attention: Sherry Ann Cavera, Relationship Manager - VP

 

Dear
Ms. Cavera:

 

In
accordance with the terms of Section 2(c) of an Escrow Deposit Agreement dated as of ________ __, 20__ (the "Escrow Agreement"),
by and among Happiness Biotech Group Limited (the “Company”), Univest Securities, LLC (“Underwriter”),
and Signature Bank (the “Escrow Agent”), the Company and Underwriter hereby notify the Escrow Agent that the ________
closing will be held on ___________ for gross proceeds of $_________.

 

PLEASE
DISTRIBUTE FUNDS BY WIRE TRANSFER AS FOLLOWS (wire instructions attached):

 

________________________:                         $

 

________________________:                         $

 

________________________:                         $

 

Very
truly yours,

 

Happiness
Biotech Group Limited

 

By:_____________

Name:__________

Title:____________

 

Univest
Securities, LLC

 

By:_____________

Name:___________

Title:____________

 

     

     

    

 

EXHIBIT
C

 

CERTIFICATE
OF AUTHORIZED REPRESENTATIVES – COMPANY

 

	Name	 	Signature	 	Initiate  (Y/N)	 	Callback 
(Y/N)	 	Phone No.	 	Alt. Phone No.
	Xuezhu Wang	 	______________

	 	XW	 	______

	 	+86 135 9939 4242		______________

	______________	 	______________	 	______	 	______

	 	______________	 	______________

	______________	 	______________	 	______	 	______

	 	______________	 	______________

	______________	 	______________	 	______	 	______

	 	______________	 	______________

	______________	 	______________	 	______	 	______

	 	______________	 	______________

 

 

 

STANDING
WIRE INSTRUCTIONS FOR COMPANY

 

In
accordance with Section 3(a) of the Agreement disbursements to Company by wire transfer must be sent in accordance with the following
wire instructions:

 

	 	Bank
    Name:	Citibank
    N.A. Hong Kong Branch
	 	Bank
    Address:	9/F
        Citi Tower, One Bay East, 83 Hoi Bun Road,

        Kwun
        Tong, Kowloon, Hong Kong

	 	ABA
    Number:	[_________]
	 	SWIFT
    CODE:	CITIHKHXXXX
	 	Account
    Number:	1093230015
	 	Account
    Name:	Happiness
    Biotech Group Limited

 

     

     

    

 

EXHIBIT
C-1

 

CERTIFICATE
OF AUTHORIZED REPRESENTATIVES – UNDERWRITER

 

	Name	 	Signature	 	Initiate

(Y/N)	 	Callback 
(Y/N)	 	Phone No.	 	Alt. Phone No.
	______________	 	______________

	 	______	 	______	 	______________	 	______________
	______________	 	______________

	 	______	 	______	 	______________	 	______________
	______________	 	______________

	 	______	 	______	 	______________	 	______________
	______________	 	______________

	 	______	 	______	 	______________	 	______________
	______________	 	______________

	 	______	 	______	 	______________	 	______________

 

 

 

STANDING
WIRE INSTRUCTIONS FOR UNDERWRITER

 

In
accordance with Section 3(a) of the Agreement disbursements to Underwriter by wire transfer must be sent in accordance with the
following wire instructions:

 

	 	Bank
    Name:	[_________]
	 	Bank
    Address:	[_________]
	 	ABA
    Number:	[_________]
	 	Account
    Number:	[_________]
	 	Account
    Name:	[_________]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]